The Melatonin Budget Impact Model (BIM) is designed to provide medicines managers, budget holders and payors with fiscal responsibility, information and insight into the Prescription Only Medicines (POM) melatonin market. It demonstrates the potential financial benefit of prescribing Slenyto® (prolonged-release melatonin) mini-tablets for patients within a local health economy instead of Circadin® 2mg, Solid Dose Melatonin IR (1) or Liquid Melatonin IR (2).
If you would like further information on how Slenyto may positively impact your local healthcare budget, or details relating to rebate, please contact Flynn Pharma on support@flynnpharma.com.
ANY TREATMENT DECISIONS INVOLVING A MEDICINE OR SUBSEQUENT INTERVENTION SHOULD BE MADE AT THE DISCRETION OF THE TREATING PHYSICIAN BASED ON PATIENT RISK/BENEFIT. THE RELEVANT SUMMARY OF PRODUCT CHARACTERISTICS SHOULD BE CONSULTED BEFORE MAKING ANY PRESCRIBING DECISIONS.
- Melatonin Capsule 2mg, Melatonin Tablet 3mg, Melatonin Capsule 3mg, Melatonin Capsule 5mg
- Melatonin Oral Solution 1mg/ml Sugar Free
